Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#2098 Systemic Anti-Cancer Therapies in Neuroendocrine Tumor Patients Impair Nutritional Status

Introduction: Malnutrition is a clinical relevant problem in NEN-patients (pts) independently influencing overall prognosis, particularly in pts undergoing chemotherapy (CTx). A poor nutritional status (NS) in pts of all WHO-grades was associated with a significantly shorter long-term outcome

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Pevny S, Maasberg S, Karber M, Knappe-Drzikova B, Weylandt K,

Keywords: nutritional status, malnutrition, chemotherapy, somatostatin analogues, everolimus, NETG1/G2, survival,

#1436 Up-Regulation of the Immunoregulatory Enzyme Indoleamine-2,3-Dioxygenase (IDO) with Consecutive Tryptophan Depletion Predicts Death in Patients with Neuroendocrine Neoplasia

Introduction: Data from a considerable number of malignancies demonstrate that depletion of the essential amino acid tryptophan via induction of the immuno-regulatory enzyme Indoleamine-2,3-dioxygenase (IDO) serves as an important tumour escape strategy and is of prognostical importance.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: unknown u

Authors: Pschowski R, Pape U, Fusch G, Jann H, Maasberg S,

Keywords: IDO-1, inflammation, tryptophan catabolites, predictor, biomarker,

#1205 Temozolomid-Based Therapy in GEP-and Bronchopulmonary NEN from a Multicentric Study from Germany

Introduction: Chemotherapy (CTx) with temozolomid as mono (TEM) or combination therapy with capcitabine (TEM/CAP) is a new cytotoxic regimen with good efficiency in pancreatic and bronchopulmonary NET-G1/G2 and NEC-G3.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Maasberg S, Bacher M, Rinke A, Lahner H, Unger N,

Keywords: temozolomide, capecitabine,

#1201 Results of Sunitinib Treatment of Advanced Neuroendocrine Neoplasms: “Real-life” Outcome Data from the German NET-Register

Introduction: Among modern treatments (Tx) for neuroendocrine neoplasms (NEN) sunitinib (SUN) has impacted Tx of primarily pancreatic NEN (pNEN).

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Bacher M, Maasberg S, Fottner C, Begum N, Quietzsch D,

Keywords: sunitinib, outcome,

#742 Evaluation of Relevant Factors of Prognosis Among a Large German Multi-Centric Cohort–Results from the German NET Registry

Introduction: Neuroendocrine neoplasms (NEN) are a rare tumor entity with varying biological behavior.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Maasberg S

Authors: Maasberg S, Begum N, Auernhammer C, Ezziddin S, Pöppel T,

Keywords: outcome, prognostic factors,